Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Non-Current Liabilities (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $959000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities fell 21.26% year-over-year to $959000.0, compared with a TTM value of $959000.0 through Sep 2025, down 21.26%, and an annual FY2024 reading of $13.8 million, down 12.29% over the prior year.
  • Other Non-Current Liabilities was $959000.0 for Q3 2025 at X4 Pharmaceuticals, up from $567000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $29.4 million in Q1 2024 and bottomed at $314000.0 in Q2 2022.
  • Average Other Non-Current Liabilities over 5 years is $7.2 million, with a median of $1.0 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities surged 8310.86% in 2024, then crashed 98.07% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $821000.0 in 2021, then surged by 2518.76% to $21.5 million in 2022, then fell by 27.06% to $15.7 million in 2023, then decreased by 12.29% to $13.8 million in 2024, then crashed by 93.03% to $959000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for XFOR at $959000.0 in Q3 2025, $567000.0 in Q1 2025, and $13.8 million in Q4 2024.